Group 1 - Lidman announced an investor survey scheduled for September 8-9 and 11-12, 2025, with the participation of Vice President and Board Secretary Zhang Lihua [1] - For the first half of 2025, Lidman's revenue composition was as follows: 86.79% from the biopharmaceutical sector, 12.96% from property leasing, and 0.25% from other businesses [1] - As of the report, Lidman's market capitalization was 4.3 billion yuan [2]

Company Overview - DaAn Gene (SZ 002030) announced its first board meeting of the ninth session held on August 28, 2025, in Guangzhou, discussing the revision and formulation of certain company systems [1] Financial Performance - For the first half of 2025, DaAn Gene's revenue composition was as follows: 95.68% from the bioproducts sector and 4.32% from financial services [1]

Group 1 - The core point of the article is that Kehua Bio (SZ 002022) announced the receipt of a medical device registration certificate for its "Human Papillomavirus Nucleic Acid Typing Detection Kit" from the National Medical Products Administration [1] - As of January to June 2025, the revenue composition of Kehua Bio is 100% from the biopharmaceutical sector [1] - Kehua Bio's market capitalization is currently 3.8 billion yuan [1] Group 2 - The pet industry is experiencing significant growth, with a market size of 300 billion yuan, leading to a surge in stock prices for related companies [1]

Group 1 - Lidman (SZ 300289, closing price: 8.89 yuan) announced on August 26 that its sixth fifth board meeting was held via communication method, discussing the proposal for the full text and summary of the 2025 semi-annual report [1] - For the year 2024, Lidman's revenue composition is as follows: 90.84% from the biopharmaceutical industry, 8.98% from property leasing, and 0.17% from services [1] - As of the report date, Lidman's market capitalization is 4.8 billion yuan [1] Group 2 - The pet industry is experiencing a significant boom, with a market size of 300 billion yuan, leading to a surge in stock prices of related listed companies [1]

Group 1 - The core point of the article is that Da An Gene has received a medical device registration certificate from the National Medical Products Administration for its "Human MTHFR Gene Typing Detection Kit" [2] - In the fiscal year 2024, Da An Gene's revenue composition is projected to be 96.2% from the biopharmaceutical sector and 3.8% from financial services [2]

Group 1 - The core point of the article is that Kehua Bio has received a medical device registration certificate from the National Medical Products Administration for its product "Treponema pallidum antibody quality control product" [2] - Kehua Bio's revenue composition for the year 2024 is expected to be 100.0% from the biopharmaceutical industry [2]

Core Insights - The company Kehua Bio-engineering has received a medical device registration certificate from the Shanghai Municipal Drug Administration for its product "C-Reactive Protein (CRP) Test Kit" [2] - For the year 2024, the company's revenue composition is expected to be 100.0% from the biopharmaceutical sector [2]

Group 1 - The core point of the article is the announcement by Kehua Bio (SZ 002022) regarding the resignation of Ms. Luo Fang as the Chief Financial Officer due to retirement, and the appointment of Mr. Zang Xianfeng as the new CFO [1] - The company's revenue composition for the year 2024 is entirely from the biological products sector, accounting for 100.0% [1] - As of the report date, Kehua Bio has a market capitalization of 3.4 billion yuan [1] Group 2 - Related news includes the appointment of Jin Xiangyu as CFO of ST Ningke [2] - Bao Xin Technology's Xu Yexiang has resigned from the positions of director and CFO [2] - Lianjiang Co. has appointed Liu Peiyuan as its CFO [2]

Group 1 - The company Kewah Bio announced the convening of its 10th Board of Directors meeting on July 31, 2025, via telecommunication voting [2] - The meeting reviewed the proposal regarding the appointment of the company's Chief Financial Officer [2] - For the year 2024, the company's revenue composition is entirely from the biopharmaceutical sector, accounting for 100.0% [2]

Group 1 - The core business of Kehua Bio is entirely focused on the biopharmaceutical sector, with a revenue composition of 100% from biological products for the year 2024 [1] Group 2 - On July 31, Kehua Bio announced the resignation of Ms. Luo Fang from the position of Chief Financial Officer due to retirement, along with her other roles in the company's subsidiaries [3] - The company has appointed Mr. Zang Xianfeng as the new Chief Financial Officer, following a nomination by the company's president and approval by the board of directors [3]